20:58 , Apr 25, 2017 |  BC Extra  |  Company News

Biogen climbs as Spinraza sales top consensus

Biogen Inc. (NASDAQ:BIIB) gained $10.03 to $286.89 after it reported 1Q17 earnings that beat a consensus estimate, including stronger than expected sales of Spinraza nusinersen. The company reported $47.4 million in sales of the spinal...
22:15 , Jan 6, 2017 |  BioCentury  |  Finance

Good riddance

  Investors aren’t lamenting the end of 2016, but they are pinned between anxiety and optimism for the year ahead. The anxiety stems from uncertainty about U.S. government policies for healthcare under the new administration. The continued...
07:00 , Sep 26, 2016 |  BC Week In Review  |  Clinical News

Opicinumab: Additional Phase II data

Additional data from the double-blind, international Phase II SYNERGY trial in 412 evaluable patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS (SPMS), showed that 10 and 30 mg/kg IV...
07:00 , Sep 16, 2016 |  BC Extra  |  Clinical News

Biogen ties anti-LINGO miss to non-linear dose response

Biogen Inc. (NASDAQ:BIIB) suggested a non-linear dose response to opicinumab ( BIIB033) could have led to the compound's failure to meet the primary endpoint in the Phase II SYNERGY study to treat relapsing forms of...
07:00 , Sep 15, 2016 |  BC Innovations  |  Targets & Mechanisms

KOR-recting MS

Although the failed Phase II multiple sclerosis trial of Biogen Inc.'s anti-LINGO mAb in June dealt a blow to myelin repair, a slew of compounds acting by different mechanisms lies behind it in clinical and...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Rethinking risk

Steve Edelson, Senior Editor   The second half does not contain the high-impact, sector-moving milestones seen in the first six months of the year, but investors still have at least 90 late-stage milestones from which to...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Shedding red

Steve Edelson, Senior Editor   Brexit nearly wiped out what looked to be a rebound quarter for biotech. Only two market cap segments finished in positive territory, and smaller companies continued to get pounded. Big caps...
07:00 , Jul 11, 2016 |  BioCentury  |  Finance

Ground up

Steve Edelson, Senior Editor   As the third quarter gets under way, biotech is shaking off the hangover of the Brexit vote while facing the overhang of the November election in the U.S. Fifteen bankers and...
07:00 , Jun 20, 2016 |  BioCentury  |  Product Development

Translating LINGO

Biogen Inc. isn't talking yet about why its anti-LINGO mAb failed a Phase II trial in the high-priority indication of multiple sclerosis, but translational researchers in the field have some ideas about knowledge gaps that...
07:00 , Jun 13, 2016 |  BC Week In Review  |  Clinical News

Opicinumab: Phase II data

Top-line data from the double-blind, international Phase II SYNERGY trial in 418 patients with relapsing forms of MS, including relapsing-remitting MS (RRMS) and secondary progressive MS, showed that IV opicinumab plus Avonex interferon...